About: Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 November 1998

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в листопаді 1998 (uk) im November 1998 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 01 November 1998 (en) artículu científicu espublizáu en payares de 1998 (ast)
publication date	wds:Q77802531-43A4938C-CDCB-4DC1-830A-86E6945803AB
publication date	1998-11-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q77802531-39B65B95-4976-41CA-8C9E-00B8F3DA9AB0
language of work or name	English
author name string	wds:Q77802531-2549F10B-EBB3-4A5D-AE97-8828142A8F70 wds:Q77802531-35AD9E72-8D4C-47F1-AFE5-566BAFE699DC wds:Q77802531-8D7A0500-037B-4512-8A4A-E8CFF2BFCEB4 wds:Q77802531-D377C2B2-C189-4D66-9686-5F0DD30C86DC
author name string	Baguley BC Wilson WR Ching LM Browne WL
rdfs:label	Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid (en) Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid (nl)
skos:prefLabel	Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid (en) Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid (nl)
name	Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid (en) Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid (nl)
title	wds:Q77802531-C14B9CC2-6E34-48B5-A17E-D60EDFBE32FF
title	Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid (en)
page(s)	wds:Q77802531-0526D84B-06E5-4DC5-9F17-4443113B10E3
page(s)	4409-4413
instance of	wds:Q77802531-9AD787A2-CB1F-4F00-9DA0-D02AD58B37B0
instance of	scholarly article
main subject	wds:Q77802531-79A7688C-FFCE-45C7-AF97-6FD5107FCC42
main subject	vascular collapse
PubMed ID	wds:Q77802531-C2986DDD-BF43-4D9A-91BF-BD2BEA0ABCA3
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9891501
PubMed ID	9891501
published in	wds:Q77802531-F7DBF359-1F89-44D2-AD70-E49D2E810E0A
published in	Anticancer Research
issue	wds:Q77802531-C9ADB2CE-A48A-4075-AAC2-CFCC057C3EF9
volume	wds:Q77802531-5E9C1B96-887C-45AB-BCA9-8E7165C277FA
issue	6A
volume	18
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q77802531
is cites work of	Potential novel uses of thalidomide: focus on palliative care Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid Aminolevulinic acid-photodynamic therapy combined with topically applied vascular disrupting agent vadimezan leads to enhanced antitumor responses The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts Thalidomide in cancer treatment: a potential role in the elderly?
is cites work of	wds:Q38289597-5E4DEF5A-9777-4C60-9E03-5AF338E2B3F2 wds:Q34303312-450D58E5-D00C-45DF-97FC-15E26F282351 wds:Q34802885-F1688D75-98B6-4B23-8646-F3102ABC64AA wds:Q36644621-E75E6758-4345-4092-BE38-0C801E55C723 wds:Q34030108-4AA39F6E-287F-4539-97EC-518731301493 wds:Q34597832-03C18068-90CD-4E22-B29B-73E05B93FE03 wds:Q36617691-31105BDF-0E9D-4CA7-B970-65EBC28AB647 wds:Q35115922-2D3BC178-8EC1-4298-9054-B738B58AA5E8

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software